Zevra Therapeutics (ZVRA) to Release Earnings on Tuesday

Zevra Therapeutics (NASDAQ:ZVRA) is projected to issue its quarterly earnings data after the market closes on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.39) per share and revenue of $8.93 million for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Zevra Therapeutics Stock Performance

NASDAQ ZVRA opened at $7.33 on Tuesday. The firm has a market capitalization of $391.25 million, a P/E ratio of -3.72 and a beta of 2.00. Zevra Therapeutics has a 1-year low of $4.20 and a 1-year high of $9.76. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The business’s 50-day simple moving average is $8.05 and its 200-day simple moving average is $8.12.

Insider Buying and Selling at Zevra Therapeutics

In other Zevra Therapeutics news, CFO R. Laduane Clifton sold 11,000 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $86,460.00. Following the transaction, the chief financial officer now directly owns 51,361 shares of the company’s stock, valued at $403,697.46. This represents a 17.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the completion of the transaction, the chief executive officer now directly owns 222,060 shares in the company, valued at approximately $1,745,391.60. The trade was a 21.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 85,773 shares of company stock valued at $674,176 in the last three months. Corporate insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

ZVRA has been the topic of several recent research reports. Canaccord Genuity Group reduced their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Guggenheim set a $21.00 price target on Zevra Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, February 4th. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Finally, Cantor Fitzgerald raised Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 29th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $21.71.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.